A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)

A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)

Abstract Background Durvalumab is a standard drug used during maintenance therapy after chemoradiotherapy in patients with locally advanced non-small cell lung cancer (LA-NSCLC). However, little is known about the clinical benefits of durvalumab after chemoradiotherapy in patients with LA-NSCLC with...

Full description

Bibliographic Details
Main Authors: Kyoichi Kaira, Atsuto Mouri, Shingo Kato, Kenichi Yoshimura, Hiroshi Kagamu, Kunihiko Kobayashi
Format: Article
Language:English
Published: BMC 2020-10-01
Series:BMC Cancer
Subjects:
Durvalumab
Chemoradiotherapy
Locally advanced non-small cell lung cancer
Elderly
PS 2
Carboplatin
Online Access:http://link.springer.com/article/10.1186/s12885-020-07406-y

Internet

http://link.springer.com/article/10.1186/s12885-020-07406-y

Similar Items